Entrada Therapeutics Inc (TRDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.31 Million) by net assets ($340.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Entrada Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Entrada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entrada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entrada Therapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Entrada Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zaggle Prepaid Ocean Services Limited
NSE:ZAGGLE
|
-0.024x |
|
ARYZTA UN.ADR 1/2 SF -02
F:YZAU
|
N/A |
|
Avjennings Ltd
AU:AVJ
|
0.025x |
|
Thye Ming Industrial Co Ltd
TW:9927
|
0.234x |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
-0.001x |
|
Ningbo GQY Video Telecom
SHE:300076
|
-0.014x |
|
STEICO SE
XETRA:ST5
|
0.153x |
|
Media and Games Invest PLC
ST:M8G
|
0.011x |
Annual Cash Flow Conversion Efficiency for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Entrada Therapeutics Inc from 2019 to 2024. View Entrada Therapeutics Inc (TRDA) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $428.68 Million | $-41.56 Million | -0.097x | -116.81% |
| 2023-12-31 | $242.36 Million | $139.80 Million | 0.577x | +230.73% |
| 2022-12-31 | $212.55 Million | $-93.79 Million | -0.441x | -159.14% |
| 2021-12-31 | $298.72 Million | $-50.86 Million | -0.170x | -127.63% |
| 2020-12-31 | $-41.49 Million | $-25.57 Million | 0.616x | -11.46% |
| 2019-12-31 | $-15.52 Million | $-10.80 Million | 0.696x | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more